Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.73% | -5.05% | 3.02% | 11.43% | 16.52% |
| Total Depreciation and Amortization | -4.94% | -1.82% | 27.31% | 24.31% | 31.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.15% | -33.26% | 7.33% | 55.48% | 91.36% |
| Change in Net Operating Assets | 82.57% | 81.00% | 15.88% | -19.79% | -326.68% |
| Cash from Operations | 19.02% | 14.33% | 11.14% | 21.95% | 12.98% |
| Capital Expenditure | -161.14% | -205.68% | -175.01% | -71.76% | 36.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | 100.00% | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 75.30% | 348.20% | 176.11% | 115.87% | 132.85% |
| Cash from Investing | 38.95% | 149.26% | 136.49% | 102.05% | 107.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -27.33% | -23.71% | -36.63% | -61.52% | -12.31% |
| Repurchase of Common Stock | 59.47% | 45.10% | 38.39% | -112.34% | -147.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -26.03% | -23.01% | -36.58% | -63.50% | -14.55% |
| Foreign Exchange rate Adjustments | -7.64% | 311.46% | -116.70% | 220.87% | 114.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -34.68% | 179.31% | 96.06% | -57.66% | 109.15% |